122 related articles for article (PubMed ID: 2533151)
1. Zoladex in advanced breast cancer.
Robertson JF; Nicholson RI; Walker KJ; Blamey RW
Horm Res; 1989; 32 Suppl 1():206-8. PubMed ID: 2533151
[TBL] [Abstract][Full Text] [Related]
2. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
Robertson JF; Walker KJ; Nicholson RI; Blamey RW
Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
[TBL] [Abstract][Full Text] [Related]
3. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex.
Robert NJ; Dalton WS; Osborne CK; Abeloff M
Horm Res; 1989; 32 Suppl 1():221-2. PubMed ID: 2533155
[TBL] [Abstract][Full Text] [Related]
4. Zoladex in the treatment of premenopausal metastatic breast cancer patients.
Kaufmann M
Horm Res; 1989; 32 Suppl 1():202-5. PubMed ID: 2533150
[TBL] [Abstract][Full Text] [Related]
5. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
6. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
[TBL] [Abstract][Full Text] [Related]
7. Effect of LHRH agonist, Zoladex, on ovarian histology.
Williamson K; Robertson JF; Ellis IO; Elston CW; Nicholson RI; Blamey RW
Br J Surg; 1988 Jun; 75(6):595-6. PubMed ID: 2969269
[TBL] [Abstract][Full Text] [Related]
8. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer.
Walker KJ; Walker RF; Turkes A; Robertson JF; Blamey RW; Griffiths K; Nicholson RI
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):651-4. PubMed ID: 2523808
[TBL] [Abstract][Full Text] [Related]
9. A multi-centre randomised study to compare the effects of ovarian ablation with Zoladex depot in pre- and perimenopausal patients with advanced breast cancer.
Tyrrell C
Horm Res; 1989; 32 Suppl 1():218-20. PubMed ID: 2533154
[TBL] [Abstract][Full Text] [Related]
10. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
11. Endocrinology of Zoladex in postmenopausal women.
Dowsett M; Cantwell BM; Harris AL
Horm Res; 1989; 32 Suppl 1():209-12. PubMed ID: 2533152
[TBL] [Abstract][Full Text] [Related]
12. Zoladex: therapeutic effects in postmenopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
[TBL] [Abstract][Full Text] [Related]
13. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
Dixon AR; Robertson JF; Jackson L; Nicholson RI; Walker KJ; Blamey RW
Br J Cancer; 1990 Nov; 62(5):868-70. PubMed ID: 2147110
[TBL] [Abstract][Full Text] [Related]
14. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
[TBL] [Abstract][Full Text] [Related]
15. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
16. LHRH analogue for treatment of recurrent and refractory mastalgia.
Hamed H; Caleffi M; Chaudary MA; Fentiman IS
Ann R Coll Surg Engl; 1990 Jul; 72(4):221-4. PubMed ID: 2143364
[TBL] [Abstract][Full Text] [Related]
17. Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer.
Nicholson RI; Walker KJ; McClelland RA; Dixon A; Robertson JF; Blamey RW
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):989-95. PubMed ID: 2149510
[TBL] [Abstract][Full Text] [Related]
18. Goserelin depot in the treatment of premenopausal advanced breast cancer.
Blamey RW; Jonat W; Kaufmann M; Bianco AR; Namer M
Eur J Cancer; 1992; 28A(4-5):810-4. PubMed ID: 1388037
[TBL] [Abstract][Full Text] [Related]
19. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
20. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]